Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
On Apr. 2, 2025, Revvity announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection.
This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world.
Tags:
Source: Revvity
Credit: Image: Scanning electron microscopic (SEM) image depicted a number of Gram-positive, Mycobacterium tuberculosis bacteria. Courtesy: Janice Haney Carr, U.S. Centers for Disease Control and Prevention.
